# Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

> **NCT02392559** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 158 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02392559
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-24
- **Primary completion:** 2019-11-25
- **Final completion:** 2019-11-25
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392559, "Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02392559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*